International Prognostic Index (IPI) for DLBCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-DLBCL-IPI |
|---|---|
| Type | Biomarker |
| Aliases | IPIInternational Prognostic Index for DLBCLNCCN-IPIR-IPIМіжнародний прогностичний індекс (IPI) для DLBCL |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | composite_score |
|---|---|
| Measurement | MethodComposite of 5 clinical variables (age >60, ECOG ≥2, LDH >ULN, stage III/IV, ≥2 extranodal sites) Unitsscore 0-5 (low / low-int / int-high / high) |
| Related biomarkers | None declared |
Notes
5-variable score: each adverse factor = 1 point. Risk groups (R-IPI): 0 = very good (5y OS ~94%); 1-2 = good (~80%); 3-5 = poor (~55%). NCCN-IPI refines age + LDH cuts; gives finer stratification. POLARIX trial used IPI ≥2 to select Pola-R-CHP over R-CHOP — primary determinant in our ALGO-DLBCL-1L decision tree.
Used By
Indications
IND-DLBCL-1L-POLA-R-CHP- IND-DLBCL-1L-POLA-R-CHPIND-DLBCL-1L-RCHOP- IND-DLBCL-1L-RCHOP
Questionnaires
QUEST-DLBCL-NOS-1L-STUB- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — first line